Fig. 2

CXCR2 is responsible for CXCL1-increased IL-6 expression in OASFs and RASFs. a, b OASFs and RASFs were pretreated with a CXCR2 inhibitor (SB225002, 5 μM) for 1 h, then incubated with CXCL1 (10 ng/mL) for 24 h. IL-6 expression levels were quantified by qPCR and Western blot. The quantification of Western blot is provided in the lower panel. c OASFs and RASFs were transfected with CXCR2 shRNA plasmids for 24 h (the knockdown efficiency was presented by Western blot), then treated with CXCL1 for 24 h. IL-6 expression levels were determined by qPCR. d The OASFs and RASFs were incubated with CXCR2 antibody, followed by treated with CXCL1 for 24 h. IL-6 expression levels were determined by qPCR. (In the above experiments, OASFs; n = 10, RASFs; n = 10). Results are expressed as the mean ± SEM. Statistical analysis was conducted by using one-way ANOVA followed by Fisher’s LSD post hoc comparisons tests. *p < 0.05 compared with the respective groups in all figures (untreated); ^#p < 0.05 compared to the groups with control (a, b), control shR (c), and IgG (d) pretreatment followed by CXCL1 incubation